Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG increased its stake in shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) by 413.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,134 shares of the company’s stock after acquiring an additional 99,158 shares during the quarter. Deutsche Bank AG owned about 0.39% of Actinium Pharmaceuticals worth $155,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Northern Trust Corp raised its stake in Actinium Pharmaceuticals by 4.9% during the 4th quarter. Northern Trust Corp now owns 251,930 shares of the company’s stock worth $317,000 after acquiring an additional 11,812 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in Actinium Pharmaceuticals during the 4th quarter worth $32,000. Creative Financial Designs Inc. ADV grew its position in Actinium Pharmaceuticals by 42.7% during the 4th quarter. Creative Financial Designs Inc. ADV now owns 91,007 shares of the company’s stock worth $115,000 after purchasing an additional 27,222 shares during the last quarter. Bank of America Corp DE grew its position in Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares during the last quarter. Finally, Los Angeles Capital Management LLC grew its position in Actinium Pharmaceuticals by 25.0% during the 4th quarter. Los Angeles Capital Management LLC now owns 213,950 shares of the company’s stock worth $270,000 after purchasing an additional 42,770 shares during the last quarter. 27.50% of the stock is currently owned by institutional investors and hedge funds.

Actinium Pharmaceuticals Stock Up 5.2%

Shares of NYSE:ATNM opened at $1.62 on Tuesday. The company has a market cap of $50.54 million, a price-to-earnings ratio of -1.17 and a beta of -0.24. The firm’s 50-day simple moving average is $1.46 and its 200-day simple moving average is $1.33. Actinium Pharmaceuticals, Inc. has a fifty-two week low of $1.03 and a fifty-two week high of $8.64.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on ATNM shares. HC Wainwright reissued a “buy” rating and set a $4.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday, May 12th. Wall Street Zen downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 12th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. According to MarketBeat, Actinium Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $4.00.

Actinium Pharmaceuticals Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).